当前位置: 首页 > 期刊 > 《胸》 > 2004年第8期 > 正文
编号:11296115
Regulation: the art of control? Regulatory T cells and asthma and allergy
http://www.100md.com 《胸》
     Correspondence to:Dr D S Robinson Leukocyte Biology Section, Biomedical Sciences Division, Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, London SW7 2AZ, UK; d.s.robinson@imperial.ac.uk

    A better understanding of the immunology of regulation may allow preventive or disease modifying treatment for asthma and other respiratory diseases

    Keywords: asthma; allergy; immunotherapy; T cells

    Much is currently made of the control of asthma in therapeutic guidelines. Both the British guidelines and the Global Initiative for Asthma (GINA) define measures of control of the disease, and recent studies have defined strategies for control using available anti-inflammatory and bronchodilator therapy such as inhaled steroids and long acting ?2 agonists.1,2 However, currently available treatments suppress inflammation but do not modify the underlying immunological predisposition to the disease.

    Asthma is widely recognised as an inflammatory airway disease driven by activation of Th2-type T lymphocytes in both atopic allergic and intrinsic or non-allergic forms.3–5 Recent advances in our understanding of the control of the immunological process have identified regulatory suppressive T cells which can prevent activation of self-reactive or pathological T cells in autoimmune or infectious disease models.6–8 Does this understanding of immune regulation hold the prospect of disease control or even prevention for asthma?

    MECHANISM OF ACTION

    The interest of immunologists in actively suppressive T cells was re-awoken by the finding by Sakaguchi and co-workers that depletion of CD4+CD25+ T lymphocytes from mice led to development of autoimmune pathology which could be prevented by re-introduction of these cells.9 Such CD4+CD25+ regulatory T cells were active in many disease models and could reverse established inflammatory diseases such as colitis.10

    These cells were shown to arise by high affinity selection in the thymus and are thought to form a "naturally occurring" regulatory population that is an important part of maintenance of tolerance or non-reactivity of the immune system against itself.11,12 Shevach and co-workers established an in vitro system and showed that CD4+CD25+ T cells failed to proliferate to polyclonal or antigenic stimulation in culture; furthermore, they could suppress proliferation and cytokine production by CD4+CD25– T cells.13 This system showed that human peripheral blood CD4+CD25+ T cells also represent a non-proliferating suppressive T cell population.14–19 The mechanism of suppression by CD4+CD25+ regulatory T cells remains unclear: in some in vivo models suppression is dependent on the immunosuppressive cytokines interleukin 10 (IL-10) and transforming growth factor ? (TGF?), whereas suppressive activity in vitro is not affected by the absence or neutralisation of these factors.7,8 In vitro suppression by both mouse and human CD4+CD25+ T cells requires contact between regulating and responding cells and is partly dependent on negative co-stimulatory signals including CTLA4 and PD-1.7 As CD25 is the alpha chain of the IL-2 receptor and these cells do not make their own IL-2, one possibility is that regulation occurs through competition for this and other T cell growth factors as well as by competition for "space" in repopulation experiments in lymphopenic mice.20 Since CD4+CD25+ T cells could regulate non-T cell dependent colitis in a mouse model, such interactions with responder T cells cannot be the sole mode of suppression and regulatory T cells are likely to influence cells of the innate immune system including dendritic cells.21 Can CD4+CD25+ T cells inhibit activation of Th2 cells in animal models or in vitro?

    Animal models

    Animal models of allergic airway sensitisation have been useful in defining potential immunological mechanisms in asthma and allergic disease.22 However, there are few data on CD4+CD25+ T cell regulation of mouse Th2 airway inflammation and airway hyperresponsiveness. When CD4+CD25+ T cells were depleted in one model airway, inflammation actually decreased.23 This may be because CD25 is also a marker of recently activated T cells or memory effector cells, so both regulators and effectors had been removed. However, co-transfer of ex vivo expanded CD4+CD25+ ovalbumin specific T cells together with Th2 cells had no effect on subsequent inhaled ovalbumin challenge in another mouse model,24 and ovalbumin specific airway CD4+CD25+ T cells in another complex double transgenic model reduced airway inflammation but not airway hyperresponsiveness in response to inhaled challenge.25

    In vitro experiments

    Human peripheral blood CD4+CD25+ T cells were shown to be suppressive in allergen stimulated cultures.26–28 We recently compared such suppressive activity in allergen stimulated in vitro cultures of CD4+CD25– and CD4+CD25+ T cells from non-atopic and atopic volunteers. CD4+CD25+ T cells suppressed proliferation and cytokine production by CD4+CD25– from non-atopic subjects almost completely, but this suppressive activity was significantly reduced in cultures from atopic volunteers, particularly when blood was taken from hay fever sufferers during the height of the pollen season.28 Interestingly, removal of CD4+CD25+ T cells from peripheral blood of non-atopic individuals revealed proliferation and Th2 cytokine production to allergen stimulation which was similar to that from atopic volunteers. These data led to the suggestion that Th2 responses to allergen in non-atopic subjects may be actively suppressed by CD4+CD25+ T cells, and that this regulation is either deficient in atopic subjects or overcome by allergen exposure. Clearly, further work is required to determine whether such regulatory cells occur in the airway or are reduced in asthma.

    Although CD4+CD25+ regulatory T cells have been isolated from lung tissue around lung cancers,29 phenotypic identification of regulatory T cells is hampered by the lack of a specific cell marker. One important advance in understanding the regulatory function of these cells came from studies of a rare human immunodefiency (IPEX) which results in autoimmune and allergic disease and its murine counterpart, the "scurfy" mouse strain: both were shown to result from mutation of a transcription factor termed FoxP3.30,31 Furthermore, in elegant experiments FoxP3 knockout mice were shown to lack CD4+CD25+ regulatory T cells, whereas ectopic expression of the transcription factor by retroviral transfer into CD4+CD25– T cells rendered these regulatory.32–34 How FoxP3 influences suppression is unclear, and although we and others have confirmed relative overexpression of mRNA for FoxP3 by human CD4+CD25+ T cells,28 this may not represent a specific marker for this cell type35 nor does it appear to be active in suppression by other regulatory T cell subtypes. Recently, neuropilin-1 was identified as a potential surface marker for mouse CD4+CD25+ T cells.36

    It is therefore possible that atopy (and asthma) result from a failure to suppress inappropriate Th2 responses to environmental allergens. What factors determine the balance between regulatory and potentially immunopathogical Th2 responses to allergen exposure in the developing (or mature) immune system? Increasing interest has focused on the mode of activation of the innate immune system (including airway dendritic cells) as a major determinant of the type of T cell response to antigen exposure. As well as the route, dose and frequency of antigen exposure, co-activation of pattern recognition receptors such as Toll-like receptors (TLR) or co-stimulatory molecules act as important determinants of T cell activation.37 It is possible that relative levels of activation of these receptors may be relevant—for example, low dose bacterial lipopolysaccharide (LPS) acting through TLR4 favours Th2 development38 whereas higher doses drive Th1 development and exposure of dendritic cells to LPS can overcome regulation by CD4+CD25+ T cells.39,40 Similarly, the balance of co-stimulation may be important as ICOS co-stimulation is active in supporting Th2 responses but can also drive development of IL-10 producing regulatory T cells in the mouse lung.41 Such considerations may provide an immunological basis for the hygiene hypothesis for the increasing prevalence of asthma and allergic disease: this may represent a failure of development of appropriate regulatory responses due to lack of appropriate TLR or co-stimulator activation at the time of allergen exposure.42 It may also underlie some of the genetic associations of asthma as with TLR2 or CD14 (an LPS receptor) polymorphisms.43,44 It is noteworthy that high exposure to cat allergen reduces the risk of IgE sensitisation and induces an IL-10 predominant "modified Th2" response which may represent regulation.45 However, such a protective effect of high level allergen exposure is not reported for house dust mite. Much more work is required before exposure to allergen or other factors can be manipulated to prevent allergic sensitisation.

    CLINICAL IMPLICATIONS

    How might regulatory T cells be manipulated or induced for treatment or prevention of asthma? Although CD4+CD25+ T cells do not proliferate in vitro in many systems, it has recently been shown that human cells can be expanded in response to antigen46 and CD4+CD25+ T cells do proliferate upon in vivo transfer to mice.47 It is suggested that suppression by CD4+CD25+ T cells is not antigen specific once these cells are activated, and it might be feasible to transfer cells expanded ex vivo. However, such cell therapy would be complex and potentially hazardous. Another approach is to induce a regulatory population in vivo. Such "adaptive" regulatory T cells have been described in vivo in mice and in vitro in mice and humans and include a range of subtypes that are distinct from the "naturally occurring" CD4+CD25+ T cells.12 For example, IL-10 producing regulatory T cells were derived in vitro from both human and mouse T cells by activation in the presence of dexamethasone and vitamin D3 (which inhibit development of Th2 and Th1 cells, respectively).48 This raises the possibility of inducing similar cells by in vivo allergen exposure in the face of immunosuppressive agents. We recently showed that in vitro exposure of CD4+CD25+ T cells to corticosteroids increased their suppressive activity in subsequent allergen stimulated cultures through increased IL-10 production.49 IL-10 producing regulatory T cell clones were produced by activation in the presence of IL-10: these Tr1 cells prevented IgE and Th2 expansion in a mouse model of allergic airways disease but also produced both IL-5 and interferon .50,51 Animal models of tolerance involving nasal or oral delivery of protein or peptide also induce regulatory T cell populations—either IL-10 producing T cells or Th3 cells making TGF?.52,53 For many years allergen injection immunotherapy has been used to control allergic diseases including rhinitis and seasonal asthma,54,55 and this treatment produces long lasting clinical effects and a reduction in Th2 responses to allergen exposure. Allergen immunotherapy also induces a predominant IL-10 response to allergen, and this may be associated with development of regulatory T cells which were CD4+CD25+.56,57 Whether this phenotype relates to CD4+CD25+ regulatory T cells or represents activation by allergen remains to be determined, although no difference was found in the suppressive activity of peripheral blood CD4+CD25+ T cells from hay fever patients who had or had not been treated with immunotherapy.58 Allergen immunotherapy is not used for asthma treatment in the UK because of the risk of anaphylaxis,59 but a number of modifications may allow its development for asthma. One approach is to break the allergen into short peptides which retain T cell reactivity but which no longer crosslink IgE (so it will not trigger anaphylaxis).60 This approach shows some efficacy in reducing airway hyperresponsiveness and reduced peripheral blood Th2 responses to allergen, again with an increase in IL-10 production.61,62 We recently showed that reduced CD4+ T cell responses to cat allergen following peptide therapy were not associated with changes in suppression by blood CD4+CD25+ T cells,63 so this type of immunotherapy may induce other regulatory T cell subtypes (or work in another fashion). Other approaches are a combination of immunotherapy with adjuvants such as CpG oligonucleotides (which activate TLR9) or mycobacterial products.64,65 Clearly, it will be important to establish both safety and bystander suppression of other allergens or antigens before these approaches can be used clinically. However, it is interesting that allergen immunotherapy reduced the development of both new allergen sensitisation and of asthma in trials in children with allergic rhinitis, which suggests that immune modulation may hold the potential to prevent asthma.66,67

    CONCLUSIONS

    Current data support the suggestion that regulatory T cells may be important in preventing allergic sensitisation in non-allergic individuals. If the balance between regulation and activation of Th2 T cells can be manipulated, this holds great promise for treatment and prevention of asthma. Regulatory T cells may also be important for a number of other lung diseases: CD4+CD25+ T cells isolated from lung tissue around lung cancers suppressed anti-tumour responses and temporary inactivation of such suppression may be useful for treatment.29 It is also possible that airway inflammation in chronic obstructive pulmonary disease results from a failure to suppress T cell responses to host antigens revealed or altered by smoking or infection. Understanding and manipulation of immune regulation will form a key part in the development of new treatments in coming years.

    FOOTNOTES

    DSR is supported in part by a Research Leave Award for Clinical Academics from the Wellcome Trust, UK.

    REFERENCES

    British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003;58 (Suppl 1) :i1–94.

    Bousquet J . Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30 (Suppl 1) :2–5.

    Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298–304.

    Robinson DS. Th-2 cytokines in allergic disease. Br Med Bull 2000;56:956–68.

    Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350–62.

    Sakaguchi S . Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455–8.

    Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389–400.

    Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816–22.

    Sakaguchi S , Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–64.

    Mottet C , Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003;170:3939–43.

    Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2:301–6.

    Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253–7.

    Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287–96.

    Levings MK, Sangregorio R, Roncarolo M - G. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295–302.

    Jonuleit H , Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285–94.

    Stephens LA, Mottet C, Mason D, et al. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001;31:1247–54.

    Dieckmann D , Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med 2001;193:303–10.

    Taams LS, Smith J, Rustin MH, et al. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001;31:1122–31.

    Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001;98:2736–44.

    Barthlott T , Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003;197:451–60.

    Maloy KJ, Salaun L, Cahill R, et al. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003;197:111–9.

    Lloyd CM, Gonzalo JA, Coyle AJ, et al. Mouse models of allergic airway disease. Adv Immunol 2001;77:263–95.

    Suto A , Nakajima H, Kagami SI, et al. Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am J Respir Crit Care Med 2001;164:680–7.

    Jaffar Z , Sivakuru T, Roberts K. CD4+CD25+ T cells regulate airway eosinophilic inflammation by modulating the Th2 cell phenotype. J Immunol 2004;172:3842–9.

    Hadeiba H , Locksley RM. Lung CD25 CD4 regulatory T cells suppress type 2 immune responses but not bronchial hyperreactivity. J Immunol 2003;170:5502–10.

    Tiemessen MM, Van Hoffen E, Knulst AC, et al. CD4 CD25 regulatory T cells are not functionally impaired in adult patients with IgE-mediated cow’s milk allergy. J Allergy Clin Immunol 2001;110:934–6.

    Bellinghausen I , Klostermann B, Knop J, et al. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol 2003;111:862–8.

    Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608–15.

    Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272–6.

    Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20–1.

    Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68–73.

    Hori S , Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–61.

    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–6.

    Khattri R , Cox T, Yasayko SA, et al. An essential role for scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337–42.

    Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003;112:1437–43.

    Bruder D , Probst-Kepper M, Westendorf AM, et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623–30.

    O’Garra A . Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8:275–83.

    Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196:1645–51.

    Pasare C , Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003;15:677–82.

    Pasare C , Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033–6.

    Akbari O , Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002;8:1024–32.

    Umetsu DT, McIntire JJ, Akbari O, et al. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002;3:715–20.

    Baldini M , Lohman IC, Halonen M, et al. A polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976–83.

    Eder W , Klimecki W, Yu L, et al. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004;113:482–8.

    Platts-Mills T , Vaughan J, Squillace S, et al. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001;357:752–6.

    Jiang S , Camara N, Lombardi G, et al. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003;102:2180–6.

    Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003;198:249–58.

    Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603–16.

    Robinson DS, Nguyen XD. Fluticasone propionate increases suppression of allergen-driven T cell proliferation by CD4+CD25+ T cells. J Allergy Clin Immunol 2004;113 (suppl) :1190 abstract.

    Groux H , O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–42.

    Cottrez F , Hurst SD, Coffman RL, et al. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000;165:4848–53.

    Sundstedt A , O’Neill EJ, Nicolson KS, et al. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 2003;170:1240–8.

    Chen Y , Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237–40.

    Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–75.

    Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001;107:87–93.

    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255–61.

    Jutel M , Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–14.

    Ling EM, Calderon M, Nguyen D, et al. Allergen immunotherapy increases suppressive activity by CD4+CD25-, IL-10 producing T cells but does not affect suppression by CD4+CD25+ T cells. J Allergy Clin Immunol 2004;113 (suppl) :330 abstract.

    BSACI Working Party. Position paper on allergen immunotherapy. Clin Exp Allergy 1993;23 (Suppl 3) :1–44.

    Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885–94.

    Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47–53.

    Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734–9.

    Smith TRF, Alexander C, Kay AB, et al. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+CD25+ T cells. Allergy 2004; (in press).

    Tighe H , Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124–34.

    Zuany-Amorim C , Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002;8:625–9.

    Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392–7.

    Moller C , Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251–6.(D S Robinson)